| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
Articles |
Department of Functional Genetics, Glaxo Wellcome Inc., Research Triangle Park, North Carolina 27709
Abstract
Polo-like kinase 1 (PLK1), which has been shown to have a critical role in mitosis, is one possible target for cancer therapeutic intervention. PLK1, at least in Xenopus, starts the mitotic cascade by phosphorylating and activating cdc25C phosphatase. Also, loss of PLK1 function has been shown to induce mitotic catastrophe in a HeLa cervical carcinoma cell line but not in normal Hs68 fibroblasts. We wanted to understand whether the selective mitotic catastrophe in HeLa cells could be extended to other tumor types, and, if so, whether it could be attributable to a tumor-specific loss of dependence on PLK1 for cdc25C activation. When PLK1 function was blocked through adenovirus delivery of a dominant-negative gene, we observed tumor-selective apoptosis in most tumor cell lines. In some lines, dominant-negative PLK1 induced a mitotic catastrophe similar to that published in HeLa cells (K. E. Mundt et al., Biochem. Biophys Res. Commun., 239: 377–385, 1997). Normal human mammary epithelial cells, although arrested in mitosis, appeared to escape the loss of centrosome maturation and mitotic catastrophe seen in tumor lines. Mitotic phosphorylation of cdc25C and activation of cdk1 was blocked by dominant-negative PLK1 in human mammary epithelial cells as well as in the tumor lines regardless of whether they underwent mitotic catastrophe. These data strongly argue that the mitotic catastrophe is not attributable to a lack of dependence for PLK1 in activating cdc25C.
This article has been cited by other articles:
 |
|
 |
|
  H. Yim and R. L. Erikson Polo-Like Kinase 1 Depletion Induces DNA Damage in Early S Prior to Caspase Activation Mol. Cell. Biol., May 15, 2009; 29(10): 2609 - 2621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Sherwood, R. Manbodh, C. Sheppard, and A. D. Chalmers RASSF7 Is a Member of a New Family of RAS Association Domain-containing Proteins and Is Required for Completing Mitosis Mol. Biol. Cell, April 1, 2008; 19(4): 1772 - 1782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Leoni, B. Bailey, J. Reifert, H. H. Bendall, R. W. Zeller, J. Corbeil, G. Elliott, and C. C. Niemeyer Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents Clin. Cancer Res., January 1, 2008; 14(1): 309 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Stegmeier, M. E. Sowa, G. Nalepa, S. P. Gygi, J. W. Harper, and S. J. Elledge The tumor suppressor CYLD regulates entry into mitosis PNAS, May 22, 2007; 104(21): 8869 - 8874. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Lansing, R. T. McConnell, D. R. Duckett, G. M. Spehar, V. B. Knick, D. F. Hassler, N. Noro, M. Furuta, K. A. Emmitte, T. M. Gilmer, et al. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1 Mol. Cancer Ther., February 1, 2007; 6(2): 450 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kappel, Y. Matthess, B. Zimmer, M. Kaufmann, and K. Strebhardt Tumor inhibition by genomically integrated inducible RNAi-cassettes Nucleic Acids Res., September 11, 2006; 34(16): 4527 - 4536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Spankuch, S. Heim, E. Kurunci-Csacsko, C. Lindenau, J. Yuan, M. Kaufmann, and K. Strebhardt Down-regulation of Polo-like Kinase 1 Elevates Drug Sensitivity of Breast Cancer Cells In vitro and In vivo Cancer Res., June 1, 2006; 66(11): 5836 - 5846. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Malorni and C. Fiorentini Is the Rac GTPase-activating toxin CNF1 a smart hijacker of host cell fate? FASEB J, April 1, 2006; 20(6): 606 - 609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Y. Chuang, X. Chen, M.-H. Tsai, H. Yan, C.-Y. Li, J. B. Mitchell, H. Nagasawa, P. F. Wilson, Y. Peng, M. M. Fitzek, et al. Abnormal gene expression profiles in unaffected parents of patients with hereditary-type retinoblastoma. Cancer Res., April 1, 2006; 66(7): 3428 - 3433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Bhonde, M.-L. Hanski, J. Budczies, M. Cao, B. Gillissen, D. Moorthy, F. Simonetta, H. Scherubl, M. Truss, C. Hagemeier, et al. DNA Damage-induced Expression of p53 Suppresses Mitotic Checkpoint Kinase hMps1: THE LACK OF THIS SUPPRESSION IN p53MUT CELLS CONTRIBUTES TO APOPTOSIS J. Biol. Chem., March 31, 2006; 281(13): 8675 - 8685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Eckerdt, J. Yuan, K. Saxena, B. Martin, S. Kappel, C. Lindenau, A. Kramer, S. Naumann, S. Daum, G. Fischer, et al. Polo-like Kinase 1-mediated Phosphorylation Stabilizes Pin1 by Inhibiting Its Ubiquitination in Human Cells J. Biol. Chem., November 4, 2005; 280(44): 36575 - 36583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Guan, P. Tapang, J. D. Leverson, D. Albert, V. L. Giranda, and Y. Luo Small Interfering RNA-Mediated Polo-Like Kinase 1 Depletion Preferentially Reduces the Survival of p53-Defective, Oncogenic Transformed Cells and Inhibits Tumor Growth in Animals Cancer Res., April 1, 2005; 65(7): 2698 - 2704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Mook Jr. The Importance and Complexities of Target Class Selectivity in Drug Discovery Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 223 - 226. [Full Text] [PDF]
|
|
|
|
|
|
L. Tsvetkov and D. F. Stern Interaction of Chromatin-associated Plk1 and Mcm7 J. Biol. Chem., March 25, 2005; 280(12): 11943 - 11947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Gunawardena, H. Siddiqui, D. A. Solomon, C. N. Mayhew, J. Held, S. P. Angus, and E. S. Knudsen Hierarchical Requirement of SWI/SNF in Retinoblastoma Tumor Suppressor-mediated Repression of Plk1 J. Biol. Chem., July 9, 2004; 279(28): 29278 - 29285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Gray Jr, D. J. Bearss, H. Han, R. Nagle, M.-S. Tsao, N. Dean, and D. D. Von Hoff Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer Mol. Cancer Ther., May 1, 2004; 3(5): 641 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Spankuch-Schmitt, J. Bereiter-Hahn, M. Kaufmann, and K. Strebhardt Effect of RNA Silencing of Polo-Like Kinase-1 (PLK1) on Apoptosis and Spindle Formation in Human Cancer Cells J Natl Cancer Inst, December 18, 2002; 94(24): 1863 - 1877. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-S. Seong, K. Kamijo, J.-S. Lee, E. Fernandez, R. Kuriyama, T. Miki, and K. S. Lee A Spindle Checkpoint Arrest and a Cytokinesis Failure by the Dominant-negative Polo-box Domain of Plk1 in U-2 OS Cells J. Biol. Chem., August 23, 2002; 277(35): 32282 - 32293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Yuan, A. Kramer, F. Eckerdt, M. Kaufmann, and K. Strebhardt Efficient Internalization of the Polo-Box of Polo-like Kinase 1 Fused to an Antennapedia Peptide Results in Inhibition of Cancer Cell Proliferation Cancer Res., August 1, 2002; 62(15): 4186 - 4190. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
